Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NFS-19
- Development stage
- Preclinical
- Lead developer
- Neurophth
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Ophthalmic
01
Overview
NFS-19 is a preclinical gene therapy candidate developed by Neurophth Therapeutics (Wuhan Kaidejinuo Biotechnology). The asset utilizes an adeno-associated virus (AAV) vector for the delivery of therapeutic genetic material. While the specific molecular target and primary clinical indication have not been publicly disclosed, Neurophth specializes in the development of gene therapies for ophthalmic conditions, such as Leber hereditary optic neuropathy (LHON) and other retinal disorders. The development of NFS-19 is currently in the preclinical stage, focusing on establishing the safety and efficacy profile required for potential clinical advancement.
Beyond the preview
Go deeper on NFS-19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NFS-19.